EU regulators back uses for AZ's Lynparza in prostate and ov...

AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s busy pipeline is producing successes in other areas.

Poseida Therapeutics aims for $115m stock market launch to f...

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR

Mixed results for Roche drugs in prostate cancer and COVID-1...

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug achieved only one of its targets and its inflammatory

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer. 

Xtandi takes fight to prostate cancer rivals with survival d...